Wockhardt Cited by FDA for Quality Control Failures - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Wockhardt Cited by FDA for Quality Control Failures


FDA has posted a Form 483 issued in March 2014 to Wockhardt’s Morton Grove Pharmaceuticals facility. Detailed in the FDA-483 are a variety of quality control, GMP, and sanitation issues observed during an investigation conducted from January to March 2014. Observations included using chromatography testing and stability monitoring procedures for which the company previously received FDA warning letters at two other plants.  Specifically, the company has been using “trial” injections during chromatography testing without proper documentation procedures.

The FDA-483 also noted the company had not properly followed stability testing programs and had failed to properly review batch discrepancies and document out-of-specification investigations. To further the quality problems noted, the FDA investigator stated that the quality control unit did not fully investigate errors, and operating procedures were not properly updated when changes occurred.

The company was also cited for failure to maintain clean and sanitary conditions, including observations of mold and improperly sanitized equipment. The FDA inspector also cited improper personnel gowning and health habits.

Source: FDA.gov

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
27%
Breakthrough designations
9%
Protecting the supply chain
41%
Expedited reviews of drug submissions
9%
More stakeholder involvement
14%
View Results
Jim Miller Outsourcing Outlook Jim Miller Health Systems Raise the Bar on Reimbursing New Drugs
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerThe Mainstreaming of Continuous Flow API Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler Industry Seeks Clearer Standards for Track and Trace
Siegfried Schmitt Ask the Expert Siegfried SchmittData Integrity
Sandoz Wins Biosimilar Filing Race
NIH Translational Research Partnership Yields Promising Therapy
Clusters set to benefit from improved funding climate but IP rights are even more critical
Supplier Audit Program Marks Progress
FDA, Drug Companies Struggle with Compassionate Use Requests

Click here